← United States · Coverage record
US · SEC FORM 4
Generate Biomedicines, Inc.
GENB · Nasdaq · CIK 0002100782 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
1 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-04 · Nally Michael.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 7,417,094
- Previous report
- 7,180,013
- Avg daily volume
- 1,289,467
- Days to cover
- 5.8
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Nally Michael | Purchase (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC filing ↗ |
| 2026-03-02 | Silvers Jason | Purchase (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC filing ↗ |
| 2026-03-02 | Mendillo Jane L | Purchase (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC filing ↗ |
| 2026-03-02 | Grous Beth | Purchase (P) | Common Stock | 300 | USD 16.00 | USD 4,800 | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
Form 4 evidence
18 transaction lines in the latest 365-day window; 18 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | Sale (S) | Common Stock | 1,000 | USD 16.00 | USD 16,000 | SEC filing ↗ |
| 2026-03-04 | Nally Michael | Purchase (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC filing ↗ |
| 2026-03-02 | Silvers Jason | Purchase (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC filing ↗ |
Show recent Form 4 evidence (11 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | Sale (S) | Common Stock | 1,000 | USD 16.00 | USD 16,000 | SEC filing ↗ |
| 2026-03-04 | Nally Michael | Purchase (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC filing ↗ |
| 2026-03-02 | Silvers Jason | Purchase (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC filing ↗ |
| 2026-03-02 | Nally Michael | C (C) | Common Stock | 658,327 | USD — | USD — | SEC filing ↗ |
| 2026-03-02 | Mendillo Jane L | Purchase (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC filing ↗ |
| 2026-03-02 | Grous Beth | Purchase (P) | Common Stock | 300 | USD 16.00 | USD 4,800 | SEC filing ↗ |
| 2026-03-02 | Bancel Stephane | C (C) | Common Stock | 724,160 | USD — | USD — | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | C (C) | Common Stock | 30,191,407 | USD — | USD — | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | C (C) | Common Stock | 30,191,407 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | GENB |
| CIK | 0002100782 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 18 transaction lines from 2026-03-02 to 2026-09-01 7 P purchase lines · 1 S sale lines · 10 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.